Physician profile
Stephen B Malone
NPI 1538109665
$5,264.91
in general payments reported to CMS, 2019-2025
35 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $1,064 · 2021: $1,433 · 2022: $463 · 2023: $14.39 · 2024: $69.42 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,160.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $551.59 | 2019-2022 | |
| Pfizer INC. | $411.20 | 2019-2025 | |
| Amgen INC. | $393.60 | 2019-2025 | Krystexxa |
| Astellas Pharma US INC | $322.51 | 2019-2021 | |
| Abbvie INC. | $303.65 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $208.45 | 2019-2022 | |
| Allergan, INC. | $179.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.14 | 2019-2022 | |
| Lilly USA, LLC | $154.05 | 2019-2021 | |
| Eisai INC. | $134.17 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $88.49 | 2019-2022 | |
| Boston Scientific Corporation | $85.90 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $69.89 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $69.42 | 2024 | Daybue |
| Janssen Pharmaceuticals, INC | $66.50 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $65.46 | 2019-2020 | |
| Esperion Therapeutics, INC. | $64.93 | 2020-2021 | |
| Amarin Pharma, INC. | $55.61 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $52.99 | 2022 | |
| Radius Health, INC. | $45.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $44.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $44.25 | 2021 | |
| Endo Pharmaceuticals INC. | $42.86 | 2019 | |
| Genentech USA, INC. | $33.86 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $29.65 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $23.99 | 2021 | |
| Glaxosmithkline, LLC. | $23.16 | 2021 | |
| Aytu Biopharma, INC. | $15.00 | 2020 | |
| Metuchen Pharmaceuticals | $13.95 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.94 | 2019 | |
| Hikma Pharmaceuticals USA | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.